section name header

Pronunciation ⬇

gem-FYE-broe-zil

Classifications ⬆ ⬇

Therapeutic Classification: lipid-lowering agents

Pharmacologic Classification: fibric acid derivatives

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Inhibits peripheral lipolysis.
  • Decreases triglyceride production by the liver.
  • Decreases production of the triglyceride carrier protein.
  • Increases HDL-C.
Therapeutic effects:
  • Decreased plasma triglycerides and increased HDL-C.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed after oral administration.

Distribution: Unknown.

Metabolism/Excretion: Some metabolism by the liver, 70% excreted by the kidneys (mostly unchanged), 6% excreted in feces.

Half-Life: 1.3–1.5 hr.

Time/Action Profile ⬆ ⬇

(triglyceride-lowering effect)

ROUTEONSETPEAKDURATION
PO2–5 days4 wkseveral mo



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: alopecia, rash, urticaria

EENT: blurred vision

GI: abdominal pain, diarrhea, epigastric pain, flatulence, gallstones, heartburn, nausea, vomiting

Hemat: anemia, leukopenia

MS: myositis

Neuro: dizziness, headache

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Lopid

Code ⬆

NDC Code